| scholarly article | Q13442814 |
| P356 | DOI | 10.1161/01.CIR.91.7.1952 |
| P698 | PubMed publication ID | 7895352 |
| P50 | author | Murray A. Mittleman | Q87967265 |
| Peter Wilson | Q89854449 | ||
| Izabella Lipinska | Q114427802 | ||
| James E. Muller | Q6133162 | ||
| P2093 | author name string | P Xu | |
| D Levy | |||
| F K Welty | |||
| P Sutherland | |||
| O C Gebara | |||
| T Matheney | |||
| P433 | issue | 7 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | estrogen | Q277954 |
| P304 | page(s) | 1952-1958 | |
| P577 | publication date | 1995-04-01 | |
| P1433 | published in | Circulation | Q578091 |
| P1476 | title | Association between increased estrogen status and increased fibrinolytic potential in the Framingham Offspring Study | |
| P478 | volume | 91 |
| Q34577461 | A comprehensive view of sex-specific issues related to cardiovascular disease |
| Q73364939 | Acute Coronary Syndromes: Molecular Basis for Cardiac Risk Factors |
| Q48446682 | Before-after study of a restricted fluid infusion strategy for management of donor hepatectomy for living-donor liver transplantation |
| Q43602399 | Bradykinin stimulates the release of tissue plasminogen activator in human coronary circulation: effects of angiotensin-converting enzyme inhibitors |
| Q33742238 | Cardiovascular pharmacology of hormone replacement therapy |
| Q35585785 | Cardiovascular risk in women with type 2 diabetes. |
| Q33714865 | Combination therapy of 17beta-estradiol and recombinant tissue plasminogen activator for experimental ischemic stroke |
| Q92127319 | Combined but not single treatment with ethinylestradiol/levonorgestrel and spironolactone reduces plasminogen activator inhibitor-1 in insulin-resistant ovariectomised rats |
| Q31154663 | Does the sex of acute stroke patients influence the effectiveness of rt-PA? |
| Q74296178 | Effects of hormone replacement therapy on cardiovascular risk factors in postmenopausal women |
| Q71720344 | Effects of hormone replacement therapy on the circadian pattern of atherothrombotic risk factors |
| Q73833388 | Effects of hormone-replacement therapy on hemostatic factors, lipid factors, and endothelial function in women undergoing surgical menopause: implications for prevention of atherosclerosis |
| Q73924556 | Effects of simvastatin or hormone replacement therapy, or both, on fibrinogen, factor VII, and plasminogen activator inhibitor levels in postmenopausal women with proven coronary artery disease |
| Q35658814 | Epistatic effects of polymorphisms in genes from the renin-angiotensin, bradykinin, and fibrinolytic systems on plasma t-PA and PAI-1 levels. |
| Q71975643 | Estrogen replacement therapy after coronary angioplasty in women |
| Q77178149 | Estrogen replacement therapy and outcome of coronary balloon angioplasty in postmenopausal women |
| Q37286107 | Estrogen-eluting stents |
| Q35838049 | Fatty Acid Oxidation and Cardiovascular Risk during Menopause: A Mitochondrial Connection? |
| Q35567290 | Fibrinolytic potential is significantly increased by oestrogen treatment in postmenopausal women with mild dyslipidaemia. |
| Q78020593 | Fibrinolytic variables in postmenopausal women with unstable coronary artery disease |
| Q73022227 | Gender differences in blood thrombogenicity in hyperlipidemic patients and response to pravastatin |
| Q48250034 | Gender differences in coagulation and fibrinolysis in white subjects with acute ischemic stroke. |
| Q37383757 | Growth factor activation of the estrogen receptor in vascular cells occurs via a mitogen-activated protein kinase-independent pathway |
| Q41047291 | Hemostatic factors as triggers of cardiovascular events. |
| Q44439138 | Hemostatic variables ,carbohydrate metabolism and lipid profile in women with low body mass index |
| Q33843646 | Hormone replacement therapy and coronary heart disease. A new debate |
| Q34491410 | Hormone replacement therapy at the threshold of 21st century |
| Q36686804 | Hormone therapy and cardiovascular disease |
| Q46580577 | Hormone therapy and the risk of stroke after acute myocardial infarction in postmenopausal women |
| Q35134618 | Hormone therapy and venous thromboembolism |
| Q51709255 | Impact of a New Formulation of Low-Dose Micronised Medroxyprogesterone and 17-beta Estradiol on Lipid Profiles in Menopausal Women. |
| Q73677521 | Impaired ovarian function and risk factors for atherosclerosis in premenopausal women |
| Q35546640 | Implications of Gender Difference in Coronary Calcification as Assessed by CT Coronary Angiography |
| Q33726132 | Increased Serum PAI-1 Levels in Subjects with Metabolic Syndrome and Long-Term Adverse Mental Symptoms: A Population-Based Study |
| Q42364100 | Influence of Apolipoprotein E on the Lipid Profile and Postprandial Triglyceride Levels in Brazilian Postmenopausal Women With Artery Disease |
| Q74445959 | Inhibition of LDL oxidation by a new estradiol receptor modulator compound LY-139478, comparative effect with other steroids |
| Q37406181 | Male-female differences in the genetic regulation of t-PA and PAI-1 levels in a Ghanaian population |
| Q36152764 | Menopausal hormone therapy |
| Q44244537 | Oral conjugated equine estrogen increases plasma von Willebrand factor in postmenopausal women |
| Q47987181 | Oral estrogen improves serum lipids, homocysteine and fibrinolysis in elderly men. |
| Q37477171 | Overweight and effect of hormone replacement therapy on lipid profiles in postmenopausal women |
| Q34389495 | Oxidative status and cardiovascular risk in women: Keeping pink at heart. |
| Q39038954 | PPARγ activation rescues mitochondrial function from inhibition of complex I and loss of PINK1. |
| Q58551778 | Physical Activity and Physical Function: Moving and Aging |
| Q34384926 | Plasminogen activator inhibitor type-1 (part one): basic mechanisms, regulation, and role for thromboembolic disease |
| Q34376916 | Plasminogen activator inhibitor type-1 in cardiovascular disease. Status report 2001. |
| Q36744475 | Plasminogen activator inhibitor-1 4G/5G gene polymorphism and primary open-angle glaucoma |
| Q34986710 | Plasminogen activator inhibitor-1: physiologic role, regulation, and the influence of common pharmacologic agents |
| Q44563404 | Positive impact of hormone replacement therapy on the fibrinolytic system: a long-term randomized controlled study in healthy postmenopausal women |
| Q74106681 | Postmenopausal hormone therapy and coronary heart disease: clinical implications of recent randomized trial results |
| Q41723402 | Postmenopausal hormone therapy. Is it useful for coronary prevention? |
| Q64981111 | Potential role of estradiol in ovariectomy-induced derangement of renal endocrine functions. |
| Q37426381 | Prospective associations between inflammatory and hemostatic markers and physical functioning limitations in mid-life women: Longitudinal results of the Study of Women's Health Across the Nation (SWAN) |
| Q74020033 | Relation between hormone replacement therapy in women and coronary artery disease estimated by electron beam tomography |
| Q74595413 | Relation of fibrinolytic potentiation by estrogen to coagulation pathway activation in postmenopausal women |
| Q27022768 | Sex differences in stroke: the contribution of coagulation |
| Q41540436 | Sex hormones and vascular reactivity |
| Q35572899 | Sex-associated differences in the modulation of vascular risk in patients with asymptomatic carotid stenosis |
| Q37983683 | Sex-related differences in patients' responses to heart failure therapy |
| Q52599324 | The Influence of Sex in Stroke Thrombolysis: A Systematic Review and Meta-Analysis. |
| Q34666872 | The choice of hormone replacement therapy or statin therapy in the treatment of hyperlipidemic postmenopausal women |
| Q42620817 | The effects of hormone replacement therapy on hemostatic variables in women with angiographically verified coronary artery disease: results from the estrogen in women with atherosclerosis study |
| Q34049729 | The effects of hormone replacement therapy on thrombin generation, fibrinolysis inhibition, and resistance to activated protein C: prospective cohort study and review of literature |
| Q33544850 | The heart and estrogen/progestin replacement study (HERS). |
| Q34421664 | The mechanisms of thrombotic risk induced by hormone replacement therapy |
| Q39462339 | The menopause and the cardiovascular system |
| Q35617189 | The role of estrogen in cardiovascular disease |
| Q30442725 | Transgenic over-expression of plasminogen activator inhibitor-1 results in age-dependent and gender-specific increases in bone strength and mineralization |
| Q44624268 | Vitamin C improves endothelial function in healthy estrogen-deficient postmenopausal women |
| Q33801935 | Who Should Receive Hormone Replacement Therapy? |
| Q52897432 | [Estrogens for prevention of coronary heart disease?]. |
Search more.